Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 21, 2014 - Issue 1
Submit an article Journal homepage
433
Views
73
CrossRef citations to date
0
Altmetric
Research Article

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

Tilmann BochtlerAmyloidosis Center, Department of Internal Medicine, University of Heidelberg Heidelberg, Germany;Department of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany
,
Ute HegenbartAmyloidosis Center, Department of Internal Medicine, University of Heidelberg Heidelberg, Germany;Department of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany
,
Christina KunzDivision of Biostatistics, German Cancer Research Center HeidelbergGermany
,
Axel BennerDivision of Biostatistics, German Cancer Research Center HeidelbergGermany
,
Anja SeckingerDepartment of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany
,
Sascha DietrichAmyloidosis Center, Department of Internal Medicine, University of Heidelberg Heidelberg, Germany;Department of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany
,
Martin GranzowInstitute of Human Genetics, University Heidelberg HeidelbergGermany
,
Kai NebenDepartment of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany
,
Hartmut GoldschmidtDepartment of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany;National Center for Tumor Diseases HeidelbergGermany
,
Anthony D. HoDepartment of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany
,
Dirk HoseDepartment of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermany;National Center for Tumor Diseases HeidelbergGermany
,
Anna JauchInstitute of Human Genetics, University Heidelberg HeidelbergGermany
&
Stefan O. SchönlandAmyloidosis Center, Department of Internal Medicine, University of Heidelberg Heidelberg, Germany;Department of Internal Medicine, Division of Hematology/Oncology/Rheumatology, University of Heidelberg HeidelbergGermanyCorrespondence[email protected]
 show all
Pages 9-17 | Received 30 Sep 2013, Accepted 07 Oct 2013, Published online: 23 Jan 2014

Citations (73)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Shaji Kumar, Angela Dispenzieri, Divaya Bhutani, Morie Gertz, Ashutosh Wechalekar, Giovanni Palladini, Raymond Comenzo, Rafael Fonseca, Arnaud Jaccard, Efstathios Kastritis, Stefan Schönland, Charles la Porte, Huiling Pei, NamPhuong Tran & Giampaolo Merlini. (2023) Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid 30:3, pages 268-278.
Read now
Natalia Kreiniz & Morie A. Gertz. (2023) Bad players in AL amyloidosis in the current era of treatment. Expert Review of Hematology 16:1, pages 33-49.
Read now
Mario Nuvolone, Marco Basset & Giovanni Palladini. (2021) A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis. Expert Opinion on Drug Safety 20:4, pages 411-426.
Read now
Brett Dumas, Hassan Yameen, Shayna Sarosiek, J. Mark Sloan & Vaishali Sanchorawala. (2020) Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid 27:4, pages 244-249.
Read now
Marco Basset, Mario Nuvolone, Giovanni Palladini & Giampaolo Merlini. (2020) Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. Expert Review of Hematology 13:9, pages 1003-1015.
Read now
Paolo Milani, Giovanni Palladini & Giampaolo Merlini. (2018) New concepts in the treatment and diagnosis of amyloidosis. Expert Review of Hematology 11:2, pages 117-127.
Read now
Giulia Zumbo, Omid Sadeghi-Alavijeh, Philip N. Hawkins & Marianna Fontana. (2017) New and developing therapies for AL amyloidosis. Expert Opinion on Pharmacotherapy 18:2, pages 139-149.
Read now
Taxiarchis V Kourelis & Morie A Gertz. (2015) Improving strategies for the diagnosis of cardiac amyloidosis. Expert Review of Cardiovascular Therapy 13:8, pages 945-961.
Read now

Articles from other publishers (65)

Takafumi Tsushima, Toshiki Terao, Kentaro Narita, Ami Fukumoto, Daisuke Ikeda, Yuya Kamura, Ayumi Kuzume, Rikako Tabata, Daisuke Miura, Masami Takeuchi & Kosei Matsue. (2023) Clinical Characteristics and Outcomes of Cyclin D1–Positive AL Amyloidosis. American Journal of Clinical Pathology 160:2, pages 157-163.
Crossref
Haiyan He, Jing Lu, Wanting Qiang, Jin Liu, Aibin Liang & Juan Du. (2023) The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma. Journal of Clinical Medicine 12:4, pages 1624.
Crossref
Giovanni Palladini & Paolo Milani. (2023) Individualized Approach to Management of Light Chain Amyloidosis. Journal of the National Comprehensive Cancer Network 21:1, pages 91-98.
Crossref
Cameron S. Fraser, Johan K. E. Spetz, Xingping Qin, Adam Presser, Jonathan Choiniere, Chendi Li, Stacey Yu, Frances Blevins, Aaron N. Hata, Jeffrey W. Miller, Gary A. Bradshaw, Marian Kalocsay, Vaishali Sanchorawala, Shayna Sarosiek & Kristopher A. Sarosiek. (2022) Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nature Communications 13:1.
Crossref
Giovanni Palladini & Giampaolo Merlini. (2022) How I treat AL amyloidosis. Blood 139:19, pages 2918-2930.
Crossref
Charlene Lee, Annette Lam, Teresa Kangappaden, Pyper Olver, Sarah Kane, Diana Tran & Eric Ammann. (2022) Systematic literature review of evidence in amyloid light-chain amyloidosis. Journal of Comparative Effectiveness Research 11:6, pages 451-472.
Crossref
Victor H. Jimenez-Zepeda. (2022) Diagnosis and treatment of AL amyloidosis in 2022. Canadian Hematology Today.
Crossref
Foteini Theodorakakou, Despina Fotiou, Meletios A. Dimopoulos & Efstathios Kastritis. (2022) Future Developments in the Treatment of AL Amyloidosis. Hemato 3:1, pages 131-152.
Crossref
Raphael E. Szalat, Joshua Gustine, J. Mark Sloan, Camille V. Edwards & Vaishali Sanchorawala. (2021) Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab . American Journal of Hematology 97:1, pages 79-89.
Crossref
Ute Hegenbart, Marc S. Raab & Stefan O. Schönland. (2021) Treatment in AL Amyloidosis: Moving towards Individualized and Clone-Directed Therapy. Hemato 2:4, pages 739-747.
Crossref
Monique C. Minnema, Rimke Oostvogels, Reinier Raymakers & Margot Jak. (2021) Differences and Similarities in Treatment Paradigms and Goals between AL Amyloidosis and Multiple Myeloma. Hemato 2:4, pages 680-691.
Crossref
Despina Fotiou, Foteini Theodorakakou & Efstathios Kastritis. (2021) Biomarkers in AL Amyloidosis. International Journal of Molecular Sciences 22:20, pages 10916.
Crossref
Marco Basset, Christoph R. Kimmich, Nicholas Schreck, Julia Krzykalla, Tobias Dittrich, Kaya Veelken, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Carsten Müller‐Tidow, Axel Benner, Ute Hegenbart & Stefan O. Schönland. (2021) Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up. British Journal of Haematology 195:2, pages 230-243.
Crossref
Eli Muchtar, Angela Dispenzieri, Morie A. Gertz, Shaji K. Kumar, Francis K. Buadi, Nelson Leung, Martha Q. Lacy, David Dingli, Sikander Ailawadhi, P. Leif Bergsagel, Rafael Fonseca, Suzanne R. Hayman, Prashant Kapoor, Martha Grogan, Omar F. Abou Ezzeddine, Julie L. Rosenthal, Michelle Mauermann, Mustaqueem Siddiqui, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Jeremy T. Larsen, Craig B. Reeder, Rahma Warsame, Ronald S. Go, David L. Murray, Ellen D. McPhail, Surendra Dasari, Dragan Jevremovic, Robert A. Kyle, Yi Lin, John A. Lust, Stephen J. Russell, Yi Lisa Hwa, Amie L. Fonder, Miriam A. Hobbs, S. Vincent Rajkumar, Vivek Roy & Taimur Sher. (2021) Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings 96:6, pages 1546-1577.
Crossref
Vincenzo Castiglione, Maria Franzini, Alberto Aimo, Alessandro Carecci, Carlo Mario Lombardi, Claudio Passino, Claudio Rapezzi, Michele Emdin & Giuseppe Vergaro. (2021) Use of biomarkers to diagnose and manage cardiac amyloidosis. European Journal of Heart Failure 23:2, pages 217-230.
Crossref
Michael Ozga, Qiuhong Zhao, Don BensonJr.Jr., Patrick Elder, Nita Williams, Naresh Bumma, Ashley Rosko, Maria Chaudhry, Abdullah Khan, Srinivas Devarakonda, Rami Kahwash, Ajay Vallakati, Courtney Campbell, Samir V. Parikh, Salem Almaani, Jason Prosek, Jordan Bittengle, Katherine Pfund, Samantha LoRusso, Miriam Freimer, Elyse Redder, Yvonne Efebera & Nidhi Sharma. (2020) AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. Cancer Medicine 10:3, pages 965-973.
Crossref
Giovanni Palladini, Paolo Milani & Giampaolo Merlini. (2020) Management of AL amyloidosis in 2020. Hematology 2020:1, pages 363-371.
Crossref
Giovanni Palladini, Paolo Milani & Giampaolo Merlini. (2020) Management of AL amyloidosis in 2020. Blood 136:23, pages 2620-2627.
Crossref
Giada Bianchi & Shaji Kumar. (2020) Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. Hematology/Oncology Clinics of North America 34:6, pages 1009-1026.
Crossref
Despina Fotiou, Meletios Athanasios Dimopoulos & Efstathios Kastritis. (2020) Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. HemaSphere 4:4, pages e454.
Crossref
Alice Nevone, Giampaolo Merlini & Mario Nuvolone. (2020) Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Frontiers in Pharmacology 11.
Crossref
Ol’ga A. Ettinger, Gennadiy E. Gendlin, Elena A. Stepanova, Irina I. Ganieva, Svetlana V. Borisovskaya, Il’ya G. Fedorov & Igor’ G. Nikitin. (2020) Amyloid cardiomyopathy in the elderly: clinical options, difficulties in diagnosis and treatment. Medical Journal of the Russian Federation 26:1, pages 45-66.
Crossref
Laura Obici & David Adams. (2020) Acquired and inherited amyloidosis: Knowledge driving patients' care. Journal of the Peripheral Nervous System 25:2, pages 85-101.
Crossref
Oliver C. Cohen & Ashutosh D. Wechalekar. (2020) Systemic amyloidosis: moving into the spotlight. Leukemia 34:5, pages 1215-1228.
Crossref
Tereza Popkova, Roman Hajek & Tomas Jelinek. (2020) Monoclonal antibodies in the treatment of AL amyloidosis: co‐targetting the plasma cell clone and amyloid deposits. British Journal of Haematology 189:2, pages 228-238.
Crossref
Sandra Ihne, Caroline Morbach, Claudia Sommer, Andreas Geier, Stefan Knop & Stefan Störk. (2020) Amyloidosis—the Diagnosis and Treatment of an Underdiagnosed Disease. Deutsches Ärzteblatt international.
Crossref
Christoph Richard Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart & Stefan O. Schönland. (2020) Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria. Blood.
Crossref
Tobias Dittrich, Christoph Kimmich, Ute Hegenbart & Stefan O. Schönland. (2020) Prognosis and Staging of AL Amyloidosis. Acta Haematologica 143:4, pages 388-400.
Crossref
Paolo Milani & Giovanni Palladini. (2020) Conventional Therapy for Amyloid Light-Chain Amyloidosis. Acta Haematologica 143:4, pages 365-372.
Crossref
RAMAPRIYA SINNAKIROUCHENAN. 2020. Onco-Nephrology. Onco-Nephrology 67 75.e3 .
Sandra Ihne, Caroline Morbach, Laura Obici, Giovanni Palladini & Stefan Störk. (2019) Amyloidosis in Heart Failure. Current Heart Failure Reports 16:6, pages 285-303.
Crossref
Noemi Puig, Bruno Paiva, Marta Lasa, Leire Burgos, Jose J. Perez, Juana Merino, Cristina Moreno, Maria-Belen Vidriales, Dolores Gómez Toboso, Maria-Teresa Cedena, Enrique M. Ocio, Ramon Lecumberri, Alfonso García de Coca, Jorge Labrador, Maria-Esther Gonzalez, Luis Palomera, Mercedes Gironella, Valentin Cabañas, Maria Casanova, Albert Oriol, Isabel Krsnik, Albert Pérez-Montaña, Javier de la Rubia, Jose-Enrique de la Puerta, Felipe de Arriba, Felipe Prosper, Joaquin Martinez-Lopez, Quentin Lecrevisse, Javier Verde, Maria-Victoria Mateos, Juan-Jose Lahuerta, Alberto Orfao & Jesús F. San Miguel. (2018) Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia 33:5, pages 1256-1267.
Crossref
Vaishali Sanchorawala. (2019) Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Advances 3:2, pages 216-218.
Crossref
Nelson Leung, Frank Bridoux, Vecihi Batuman, Aristeidis Chaidos, Paul Cockwell, Vivette D. D’Agati, Angela Dispenzieri, Fernando C. Fervenza, Jean-Paul Fermand, Simon Gibbs, Julian D. Gillmore, Guillermo A. Herrera, Arnaud Jaccard, Dragan Jevremovic, Efstathios Kastritis, Vishal Kukreti, Robert A. Kyle, Helen J. Lachmann, Christopher P. Larsen, Heinz Ludwig, Glen S. Markowitz, Giampaolo Merlini, Peter Mollee, Maria M. Picken, Vincent S. Rajkumar, Virginie Royal, Paul W. Sanders, Sanjeev Sethi, Christopher P. Venner, Peter M. Voorhees, Ashutosh D. Wechalekar, Brendan M. Weiss & Samih H. Nasr. (2018) The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology 15:1, pages 45-59.
Crossref
Mario Nuvolone, Paolo Milani, Giovanni Palladini & Giampaolo Merlini. (2018) Management of the elderly patient with AL amyloidosis. European Journal of Internal Medicine 58, pages 48-56.
Crossref
Sandy W. Wong, Ute Hegenbart, Giovanni Palladini, Gunjan L. Shah, Heather J. Landau, Melissa Warner, Denis Toskic, Arnaud Jaccard, Timon Hansen, Joan Bladé, M. Teresa Cibeira, Efstathios Kastritis, Angela Dispenzieri, Ashutosh Wechalekar, Cindy Varga, Stefan O. Schönland & Raymond L. Comenzo. (2018) Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma Myeloma and Leukemia 18:11, pages e493-e499.
Crossref
Giampaolo Merlini, Angela Dispenzieri, Vaishali Sanchorawala, Stefan O. Schönland, Giovanni Palladini, Philip N. Hawkins & Morie A. Gertz. (2018) Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers 4:1.
Crossref
Tilmann Bochtler, Maximilian MerzThomas HielscherMartin GranzowKorbinian HoffmannAlwin Krämer, Marc-Steffen RaabJens Hillengass, Anja SeckingerChristoph KimmichTobias Dittrich, Carsten Müller-TidowDirk HoseHartmut Goldschmidt, Ute HegenbartAnna JauchStefan O. Schönland. (2018) Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Advances 2:20, pages 2607-2618.
Crossref
Maria Gavriatopoulou, Pellegrino Musto, Jo Caers, Giampaolo Merlini, Efstathios Kastritis, Niels van de Donk, Francesca Gay, Ute Hegenbart, Roman Hajek, Sonja Zweegman, Benedetto Bruno, Christian Straka, Meletios A. Dimopoulos, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Monika Engelhardt & Evangelos Terpos. (2018) European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 32:9, pages 1883-1898.
Crossref
Lindsay Hammons, Ruta Brazauskas, Marcelo Pasquini, Mehdi Hamadani, Parameswaran Hari & Anita D'Souza. (2018) Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematology/Oncology and Stem Cell Therapy 11:2, pages 105-111.
Crossref
Efstathios Kastritis, Ioannis V. Kostopoulos, Evangelos Terpos, Bruno Paiva, Despina Fotiou, Maria Gavriatopoulou, Nikolaos Kanellias, Dimitrios C. Ziogas, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Ioannis P. Trougakos, Ourania Tsitsilonis & Meletios A. Dimopoulos. (2018) Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal 8:5.
Crossref
Paolo Milani, Giampaolo Merlini & Giovanni Palladini. (2018) Novel Therapies in Light Chain Amyloidosis. Kidney International Reports 3:3, pages 530-541.
Crossref
Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Basset, Francesca Russo, Stefano Perlini & Giampaolo Merlini. (2018) Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood 131:5, pages 525-532.
Crossref
Efstathios Kastritis, Ashutosh Wechalekar & Giampaolo Merlini. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms 221 245 .
Paolo Milani, Marco Basset, Francesca Russo, Andrea Foli, Giampaolo Merlini & Giovanni Palladini. (2017) Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 130:5, pages 625-631.
Crossref
E Muchtar, A Dispenzieri, S K Kumar, R P Ketterling, D Dingli, M Q Lacy, F K Buadi, S R Hayman, P Kapoor, N Leung, R Chakraborty, W Gonsalves, R Warsame, T V Kourelis, S Russell, J A Lust, Y Lin, R S Go, S Zeldenrust, R A Kyle, S V Rajkumar & M A Gertz. (2016) Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia 31:7, pages 1562-1569.
Crossref
Chunlan Zhang, Xufei Huang & Jian Li. (2017) Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?. Blood Reviews 31:4, pages 261-270.
Crossref
Paolo Milani, Giampaolo Merlini & Giovanni Palladini. (2017) Kidney Involvement in Light Chain Amyloidosis. Journal of Onco-Nephrology 1:2, pages 110-119.
Crossref
Mathew S. MaurerPerry ElliottRaymond ComenzoMarc SemigranClaudio Rapezzi. (2017) Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation 135:14, pages 1357-1377.
Crossref
Nilay Sethi, Reza Sedighi Manesh, Adam Sperling, Scott C. Bresler, Nathan T. Connell & Lawrence M. Tierney. (2017) Factoring in the missing link. American Journal of Hematology 92:1, pages 110-113.
Crossref
Tilmann BochtlerUte HegenbartChristina KunzAxel BennerChristoph KimmichAnja SeckingerDirk HoseHartmut Goldschmidt, Martin Granzow, Peter DregerAnthony D. HoAnna Jauch & Stefan O. Schönland. (2016) Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood 128:4, pages 594-602.
Crossref
Giovanni Palladini & Giampaolo Merlini. (2016) What is new in diagnosis and management of light chain amyloidosis?. Blood 128:2, pages 159-168.
Crossref
Bruno PaivaJoaquin Martinez-LopezLuis A. CorcheteBeatriz Sanchez-VegaInmaculada RapadoNoemi PuigSantiago BarrioMaria-Luz SanchezDiego AlignaniMarta LasaAlfonso García de CocaEmilia PardalAlberto OriolMaria-Esther Gonzalez GarciaFernando EscalanteTomás J. González-LópezLuis Palomera, José Alonso, Felipe ProsperAlberto OrfaoMaria-Belen VidrialesMaría-Victoria MateosJuan-Jose LahuertaNorma C. GutierrezJesús F. San Miguel. (2016) Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood 127:24, pages 3035-3039.
Crossref
Brendan M. Weiss, Sandy W. Wong & Raymond L. Comenzo. (2016) Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood 127:19, pages 2275-2280.
Crossref
Seon Young Kim, Kyongok Im, Si Nae Park, Jung-Ah Kim, Sung-Soo Yoon & Dong Soon Lee. (2016) Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance. Leukemia Research 44, pages 45-52.
Crossref
Brandon Yim, Elizabeth Kertowidjojo, Yue Zhang & Pruthvi Patel. (2016) Poor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases. Case Reports in Oncological Medicine 2016, pages 1-5.
Crossref
Efstathios Kastritis & Meletios A. Dimopoulos. (2016) Recent advances in the management of AL Amyloidosis. British Journal of Haematology 172:2, pages 170-186.
Crossref
Angela Dispenzieri & Giampaolo Merlini. 2016. Plasma Cell Dyscrasias. Plasma Cell Dyscrasias 273 318 .
Tilmann Bochtler, Ute Hegenbart, Christina Kunz, Axel Benner & Stefan O. Schönland. (2015) Reply to R. Warsame et al. Journal of Clinical Oncology 33:33, pages 3976-3977.
Crossref
Angela Dispenzieri, Francis Buadi, Shaji K. Kumar, Craig B. Reeder, Tamur Sher, Martha Q. Lacy, Robert A. Kyle, Joseph R. Mikhael, Vivek Roy, Nelson Leung, Martha Grogan, Prashant Kapoor, John A. Lust, David Dingli, Ronald S. Go, Yi Lisa Hwa, Suzanne R. Hayman, Rafael Fonseca, Sikander Ailawadhi, P. Leif Bergsagel, Ascher Chanan-Khan, S. Vincent Rajkumar, Stephen J. Russell, Keith Stewart, Steven R. Zeldenrust & Morie A. Gertz. (2015) Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings 90:8, pages 1054-1081.
Crossref
R Warsame, S K Kumar, M A Gertz, M Q Lacy, F K Buadi, S R Hayman, N Leung, D Dingli, J A Lust, R P Ketterling, Y Lin, S Russell, L Hwa, P Kapoor, R S Go, S R Zeldenrust, R A Kyle, S V Rajkumar & A Dispenzieri. (2015) Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer Journal 5:5, pages e310-e310.
Crossref
Tilmann BochtlerUte HegenbartChristina KunzMartin GranzowAxel BennerAnja SeckingerChristoph KimmichHartmut GoldschmidtAnthony D. HoDirk HoseAnna JauchStefan O. Schönland. (2015) Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Journal of Clinical Oncology 33:12, pages 1371-1378.
Crossref
Mario Nuvolone, Giovanni Palladini & Giampaolo Merlini. 2015. Amyloid and Related Disorders. Amyloid and Related Disorders 9 29 .
Raymond L. Comenzo. (2014) Plasma Cell Neoplasms, Their Precursor States, and Their Prediction of Organ Damage. Journal of Clinical Oncology 32:25, pages 2679-2682.
Crossref
Francesca Lavatelli, Riccardo Albertini, Andrea Di Fonzo, Giovanni Palladini & Giampaolo Merlini. (2014) Biochemical markers in early diagnosis and management of systemic amyloidoses. Clinical Chemistry and Laboratory Medicine (CCLM) 52:11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.